<DOC>
	<DOC>NCT00160654</DOC>
	<brief_summary>Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.</brief_summary>
	<brief_title>Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized. Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1. Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of trial entry. Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months. Presence of known pseudoseizures within the last year. Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors. Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Keppra</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>